|Day's Range||33.75 - 34.13|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.43|
|Dividend & Yield||1.28 (3.75%)|
|1y Target Est||N/A|
In the last decade, no fewer than three major pharmaceutical companies have suffered defeat trying to bring a new class of cholesterol-lowering medication to market.s Much to the surprise of investors, Merck & Co. (MRK) could succeed where Pfizer (PFE), Roche (RHHBY) and Eli Lilly & Co. (LLY) have all failed. Merck has yet to decide if it will seek Food and Drug Administration approval, a sign to some that the company isn’t sure if the study data, though positive, are strong enough to ensure regulatory approval. Thanks to the growing success of Merck’s immunotherapy cancer drug Keytruda, the shares have gained 19% in the past year to near a 52-week high of $66.80.
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.
Pfizer was trading at a forward PE multiple of ~12.8x on June 22, 2017, compared to the industry average of ~16.6x.